Q-omics provides the consensus-scored MGAT4A profile across patient tissues and cancer cell-line models. MGAT4A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MGAT4A is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MGAT4A RNA expression shows 20,850 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KICH, and KIRP as cancer lineages where MGAT4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT4A survival associations across molecular data types. MGAT4A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT4A RNA expression–survival associations across cancer types. High MGAT4A expression shows unfavorable associations in UCEC, LIHC, UVM and LGG, but favorable associations in KIRC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MGAT4A RNA expression.
This table summarizes MGAT4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MGAT4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT4A shows lower tumor expression in KICH, COAD, KIRP and LUSC and higher tumor expression in STAD and LIHC. The KICH box plot shows higher MGAT4A RNA expression in normal versus tumor tissue (log2 FC = −2.644, t-test p < 0.001).
This table shows molecular features associated with MGAT4A in patient tissues and cancer cell lines. In patient samples, MGAT4A shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
